Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.